Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.
about
Anti-Müllerian hormone deficiency in females with Fanconi anemia.Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumorsPrediagnostic circulating anti-Müllerian hormone concentrations are not associated with prostate cancer riskReduced serum levels of anti-Müllerian hormone in females with inherited bone marrow failure syndromesAnti-Müllerian hormone concentrations in premenopausal women and breast cancer riskAnti-Proliferative and Apoptotic Activities of Müllerian Inhibiting Substance Combined with Calcitriol in Ovarian Cancer Cell Lines.The Müllerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signalingPlasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies.Definition by FSH, AMH and embryo numbers of good-, intermediate- and poor-prognosis patients suggests previously unknown IVF outcome-determining factor associated with AMH.An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance.Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancerAnti-Mullerian hormone and endometrial cancer: a multi-cohort study.Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.Does loop electrosurgical excision procedure of the uterine cervix affect anti-Müllerian hormone levels?Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.Anti-Mullerian hormone and risk of invasive serous ovarian cancer
P2860
Q33569005-92F60A8C-956E-4D4F-932A-E07C313F175CQ34246272-6FD17E4C-4E70-4373-9483-460AE564BC36Q34458280-01F49BAB-92D0-4952-ABF3-AE28D9C342AEQ35055118-B6774A38-FADA-4DA1-BE6E-10916B59041FQ35675000-D16B526C-F1F6-4566-B35A-B45EED37B692Q36418743-28A6B7AB-54D3-4A88-A656-F4609A276A06Q36435768-6913B661-3199-4423-B317-EE5C426903D3Q36917692-BB99E559-0CD5-4E68-B28A-431840F6EFAFQ36991137-3F827E74-EE1D-4106-9422-7A2F795E86A8Q37693327-48602A49-DA76-49AB-AB4C-54EAC5208D19Q39393122-018BC08C-3B27-4184-AADA-1D34D44FB003Q39542130-229B4C84-1E45-4D14-BCF6-19A177335A10Q39651067-3B4334CD-302C-4BCE-BFA4-26A2AD2FB5A8Q40057472-4B65688F-C6E3-4CEE-81B3-0D4A2A9E5A39Q40263318-D0840B11-4E4D-4A31-9611-9E85201CD2DFQ42410866-B17D4418-C196-44BE-83A4-D1445B216ADCQ47969294-68650B52-CCA7-4BFE-9727-5EB573DF65B5Q58352100-CDEFE61D-2895-49CB-8D82-754DFF305B8A
P2860
Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Müllerian inhibiting substance ...... man ovarian and other cancers.
@en
Müllerian inhibiting substance ...... man ovarian and other cancers.
@nl
type
label
Müllerian inhibiting substance ...... man ovarian and other cancers.
@en
Müllerian inhibiting substance ...... man ovarian and other cancers.
@nl
prefLabel
Müllerian inhibiting substance ...... man ovarian and other cancers.
@en
Müllerian inhibiting substance ...... man ovarian and other cancers.
@nl
P2860
P356
P1433
P1476
Müllerian inhibiting substance ...... man ovarian and other cancers.
@en
P2093
David T MacLaughlin
Patricia K Donahoe
P2860
P304
P356
10.2217/FON.09.172
P407
P577
2010-03-01T00:00:00Z